FDA Approves Lilly's Kisunla for the Treatment of Early Symptomatic Alzheimer's Disease; Kisunla is the first amyloid plaque-targeting therapy that allows for stopping treatment upon plaque removal, company says.

Media coverage

• Title	FDA Approves Lilly's Kisunla for the Treatment of Early Symptomatic Alzheimer's Disease; Kisunla is the first amyloid plaque-targeting therapy that allows for stopping treatment upon plaque removal, company says.
  Media name/outlet	Pharmaceutical Executive
  Country/Territory	United States
  Date	1/07/24
  Persons	Howard Fillit